Title : Economic burden of chronic obstructive pulmonary disease. Impact of new treatment options.

Pub. Date : 2001

PMID : 11303413






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Since the publication of these guidelines, several new pharmacological products have been approved for use in patients with COPD including a combination of an anticholinergic and selective beta 2-adrenergic agonist [ipratropium/salbutamol (albuterol)] and a long-acting beta 2-adrenergic agonist (salmeterol). Ipratropium potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens